Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004239 · ClinicalTrials.gov registry record · Phase 1
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
A Phase 1 study, sponsored by Alliance for Clinical Trials in Oncology.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00004239 is a Phase 1 study that was terminated before completion, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 10 participants.
The verdict
NCT00004239, a Phase 1 study, was terminated before completion, sponsored by Alliance for Clinical Trials in Oncology.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of 506U78 in treating patients who have hematologic cancer and kidney or liver impairment.
Interventions
- DRUG Compound 506U78
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 1999-12 |
| Est. Completion | 2002-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004239
The ClinicalTrials.gov registry entry for NCT00004239 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Compound 506U78 is the first listed.
NCT00004239 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004239 about?
NCT00004239 is a clinical study titled "506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of 506U78 in treating patients who have hematologic cancer and kidney or liver impairment.
What is the current status of trial NCT00004239?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 1999-12. Estimated completion is 2002-01.
What interventions are being tested in trial NCT00004239?
The interventions under investigation include: Compound 506U78 (DRUG).
Who is sponsoring clinical trial NCT00004239?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.